MedTrace Logo

Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries

NCT01866254 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-01-03

No results posted yet for this study

Summary

The purpose of this study is to determine if intrathecal hydromorphone will relieve pain as well as intrathecal morphine after cesarean delivery, with fewer side effects.

Conditions

Interventions

DRUG

Hydromorphone

Injection of 100 mcg hydromorphone into the intrathecal space

DRUG

Morphine

Injection of 200 mcg of intrathecal morphine

Sponsors & Collaborators

  • Masimo Corporation

    collaborator INDUSTRY

  • Grace Shih, MD

    lead OTHER

Principal Investigators

  • Grace Shih, MD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2017-12-04
Completion
2018-10-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01866254 on ClinicalTrials.gov